EA201691443A1 - Накожное восстановление иммунобаланса - Google Patents

Накожное восстановление иммунобаланса

Info

Publication number
EA201691443A1
EA201691443A1 EA201691443A EA201691443A EA201691443A1 EA 201691443 A1 EA201691443 A1 EA 201691443A1 EA 201691443 A EA201691443 A EA 201691443A EA 201691443 A EA201691443 A EA 201691443A EA 201691443 A1 EA201691443 A1 EA 201691443A1
Authority
EA
Eurasian Patent Office
Prior art keywords
balance
immuno
improve
immune balance
treatment
Prior art date
Application number
EA201691443A
Other languages
English (en)
Inventor
Люси Мондуле
Венсан Диосзеги
Пьер Анри Бенаму
Кристоф Дюпон
Original Assignee
Дбв Текнолоджиз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дбв Текнолоджиз filed Critical Дбв Текнолоджиз
Publication of EA201691443A1 publication Critical patent/EA201691443A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)

Abstract

Настоящее изобретение относится к композициям и способам улучшения состояния объекта путем накожного установления иммунобаланса. Изобретение показывает, что определенные регуляторные Т-клетки могут быть индуцированы и поддерживаться у объекта путем накожной обработки, что вызывает значительное улучшение состояния объекта. Изобретение может быть использовано в профилактическом контексте для улучшения иммунобаланса объекта и позволяет избежать наступления или развития заболеваний, а также в терапевтическом контексте для улучшения восстановления объекта. Изобретение особенно подходит для профилактики или лечения пролиферативного или аутоиммунного заболевания. Изобретение может быть использовано в любом организме млекопитающего, предпочтительно человеком, в том числе детьми и взрослыми.
EA201691443A 2014-01-17 2015-01-14 Накожное восстановление иммунобаланса EA201691443A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461928716P 2014-01-17 2014-01-17
PCT/EP2015/050594 WO2015107081A1 (en) 2014-01-17 2015-01-14 Epicutaneous immunorebalancing

Publications (1)

Publication Number Publication Date
EA201691443A1 true EA201691443A1 (ru) 2016-12-30

Family

ID=52347336

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691443A EA201691443A1 (ru) 2014-01-17 2015-01-14 Накожное восстановление иммунобаланса

Country Status (12)

Country Link
US (1) US20160331834A1 (ru)
EP (1) EP3094335A1 (ru)
JP (1) JP2017505766A (ru)
KR (1) KR20160107328A (ru)
CN (1) CN106163555A (ru)
AU (1) AU2015206046A1 (ru)
BR (1) BR112016016525A2 (ru)
CA (1) CA2936259A1 (ru)
EA (1) EA201691443A1 (ru)
IL (1) IL246499A0 (ru)
MX (1) MX2016009306A (ru)
WO (1) WO2015107081A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
WO2017210749A1 (en) * 2016-06-10 2017-12-14 Adelaide Research & Innovation Pty Ltd Methods and products for treating autoimmune diseases
EP3533451B1 (en) 2017-01-21 2022-07-27 Guangzhou Hanfang Pharmaceuticals Co., Ltd. Application of paeoniflorin-6'-o-benzene sulfonate in medicine for treating sjögren's syndrome
MA49791A (fr) 2017-07-18 2020-05-27 Before Brands Inc Procédés de fabrication de compositions d'allergènes mixtes
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
MX2021008873A (es) 2019-01-23 2021-11-04 Before Brands Inc Métodos para la preparacion de composiciones alergenicas mixtas.
US11622943B2 (en) 2019-05-10 2023-04-11 Chamkurkishtiah Panduranga Rao System and method for allergen-specific epicutaneous immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564789T3 (es) * 2004-09-15 2016-03-29 The Trustees Of The University Of Pennsylvania Métodos para el aislamiento y la expansión de células T reguladoras derivadas de sangre de cordón
JP2011519271A (ja) * 2008-04-11 2011-07-07 ユニバーシティ オブ サザン カリフォルニア エクスビボで制御性ｔ細胞の作成を加速するための方法および組成物
JP2013059295A (ja) * 2011-09-14 2013-04-04 Nagoya City Univ ｓｉＲＮＡ、抗原提示細胞、制御性Ｔ細胞及び治療薬
EP2626082A1 (en) * 2012-02-13 2013-08-14 DBV Technologies Method of preventing allergies

Also Published As

Publication number Publication date
JP2017505766A (ja) 2017-02-23
CN106163555A (zh) 2016-11-23
AU2015206046A1 (en) 2016-07-21
EP3094335A1 (en) 2016-11-23
CA2936259A1 (en) 2015-07-23
MX2016009306A (es) 2017-04-10
KR20160107328A (ko) 2016-09-13
US20160331834A1 (en) 2016-11-17
IL246499A0 (en) 2016-08-31
BR112016016525A2 (pt) 2017-08-08
WO2015107081A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
EA201691443A1 (ru) Накожное восстановление иммунобаланса
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
MX2022007522A (es) Anticuerpos anti-cd27.
EA201890111A1 (ru) Замещенные производные оксопиридина
EA201790413A1 (ru) Антитела против tigit
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201690093A1 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201691582A1 (ru) Новые фармацевтические препараты
EA201692098A1 (ru) Биокерамические композиции и их применение для биомодулирования
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
EA201790507A1 (ru) Способы и композиции для усиления иммунных ответов
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
EA201391616A1 (ru) Применение тиазолидных соединений для предотвращения и лечения вирусных заболеваний, рака и заболеваний, вызванных внутриклеточными инфекциями
PH12015502302A1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
PH12018501443A1 (en) Methods of administering hepcidin
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
EA201600288A1 (ru) Замещенные фенилаланиновые производные
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
EA201992389A1 (ru) Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение
PH12015502844A1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
MX2018013685A (es) Terapia de combinacion de cebadadura:refuerzo.
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний